For over 50 years, the Mini-Mental State Examination (MMSE) has been used as a screening tool for cognitive impairment. With dementia rates rising worldwide, many clinicians have taken to using the test as an aid in the process of diagnosing Alzheimer’s disease and other types of dementia.
While the MMSE has been shown to accurately flag symptoms of significant cognitive impairment, it doesn’t have the complexity to provide detailed information about cognitive performance or identify more subtle signs of decline. Digital cognitive testing provides a targeted look at different brain-based cognitive domains by gathering objective data to identify patterns of performance that are associated with dementia, mild cognitive impairment, and other disorders linked with cognition.
In this post, we’ll review the strengths and weaknesses of the MMSE and compare its effectiveness with modern digital tools.
Key Takeaways:
|
The MMSE is a brief cognitive assessment that was created by Marshal Folstein et al. in 1975 and continues to be used to this day. It was designed to rapidly assess the cognitive function of hospitalized psychiatric patients and record changes over time. It is now commonly used as a dementia assessment, and while it is unfortunately sometimes misunderstood as a diagnostic test, it is in fact a screening test with relatively modest sensitivity.
The MMSE includes 11 questions and can be administered in 5-10 minutes, though there is no timed element for patients. It has both verbal and written components, which cover multiple areas of cognition.
While research suggests the MMSE can accurately rule out a dementia diagnosis, it is not sensitive enough to be used as a stand‐alone test in the identification of either dementia or mild cognitive impairment.
The five components of the MMSE refer to the areas of cognitive processing that the test measures over a series of eleven questions. These components are
The Mini-Mental State Examination (MMSE) is scored with a 30-point system that is calculated based on the following:
Often, a score of 24 or higher suggests no cognitive impairment, 18 to 23 is considered to be indicative of mild cognitive impairment, and a score between 0 and 17 suggests severe cognitive impairment. However, there are multiple scoring methods and cutoff guidelines, some of which take factors like age and education into account.
The Mini-Mental State Examination (MMSE) is a widely used assessment for patients expressing concerns about their cognitive health. But as a quick pen-and-paper questionnaire, it comes with its own unique strengths and weaknesses.
Some of the strengths of the MMSE that may contribute to its popularity include:
As far as dementia assessments go, the MMSE does come with a few significant limitations. For instance, the test lacks sensitivity to frontal and executive dysfunctions, and only three points out of 30 assess memory, the domain most affected in the early stages of common forms of dementia. Some of the test’s other limitations include:
Due to these limitations, the MMSE cannot gather the detailed, objective data required to detect subtle impairment or change over time—something that digital tests designed for dementia assessment may be able to more adequately support.
The Creyos Dementia Screener and Assessment is a modern tool to support the early detection of dementia symptoms and mild cognitive impairment. Rather than relying on inconvenient, subjective pen-and-paper tests or lengthy neurocognitive testing, our digital cognitive tests offer a third option for cognitive care.
The protocol includes:
The full assessment protocol can be completed in under a half hour. As a digital test, it can be completed either virtually or in person, allowing providers to offer patients living in remote locations greater access to care—and less stress along with it.
"We administer Creyos on tablets and relate the tasks to being like puzzle games that our patients have likely played before. Because the tasks are gamified, Creyos alleviates some of the technology anxiety that our older patients have."
–Melissa Picchione of Yukon Neurology
For cognitive screening, the Creyos screener and the MMSE are both brief and easy to administer. However, cognitive screening and assessment with Creyos provides objective, detailed, scientifically backed data to aid clinicians in diagnosing and managing dementia.
Compared to the MMSE, the Creyos dementia protocol:
While the Mini Mental State Examination (MMSE) is a convenient tool for rapid cognitive screening, it is not sensitive enough to flag signs of mild cognitive impairment or early dementia and has several other limitations. By incorporating online cognitive assessments into neurology, psychiatry, or general practice, providers can accurately gather and track patient data over time.
Mike Battista specializes in brain health, cognition, and neuropsychological testing. He received his PhD in personality and measurement psychology at Western University in 2010 and has been doing fun and useful stuff in the intersection between science and technology ever since.